Atlas FDA

EXABLATE

FDA premarket approval P040003/S015 · decided 2015-08-31

Approval details

PMA number
P040003
Supplement
S015
Supplement type
Normal 180 Day Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
EXABLATE
Generic name
Ablation system, high intensity focused ultrasound (HIFU), MR-guided
Applicant
Insightec, Ltd.
Date received
2015-03-04
Decision date
2015-08-31
Days to decision
180 days
Decision code
APPR
Product code
NRZ
Advisory committee
Obstetrics/Gynecology
Expedited review
No
Location
Dallas, TX
Statement
APPROVAL FOR CHANGES TO THE INDICATIONS FOR USE STATEMENT, PHYSICIAN LABELING, AND PATIENT LABELING. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE TRADE NAME EXABLATE MAGNETIC RESONANCE GUIDED FOCUSED ULTRASOUND SYSTEM AND IS INDICATED TO ABLATE UTERINE FIBROID TISSUE IN PRE- OR PERI-MENOPAUSAL WOMEN WITH SYMPTOMATIC UTERINE FIBROIDS WHO DESIRE A UTERINE SPARING PROCEDURE AND WHOSE UTERINE SIZE IS LESS THAN 24 WEEKS.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Exablate Model 2100V1, Exablate Prostate System, Exablate MRgFUS, Exablate 2100V1 Type 3.0 (K231378)Insightec, Ltd.2023-10-30